Assenagon Asset Management S.A. Has $12.70 Million Holdings in ResMed Inc. $RMD

28 Jun 2026, 07:25 by Danessa Lincoln · The Markets Daily

Assenagon Asset Management S.A. lessened its stake in shares of ResMed Inc. (NYSE:RMD – Free Report) by 29.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 56,570 shares of the medical equipment provider’s stock after selling 24,099 shares during the quarter. Assenagon Asset Management S.A.’s holdings in ResMed were worth $12,699,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. First Trust Advisors LP lifted its holdings in ResMed by 240.9% during the 4th quarter. First Trust Advisors LP now owns 1,517,592 shares of the medical equipment provider’s stock worth $365,542,000 after buying an additional 1,072,394 shares during the period. Norges Bank bought a new position in ResMed during the fourth quarter worth $249,068,000. Deutsche Bank AG grew its stake in shares of ResMed by 126.0% in the 4th quarter. Deutsche Bank AG now owns 1,413,477 shares of the medical equipment provider’s stock valued at $340,464,000 after buying an additional 787,949 shares during the period. Morgan Stanley increased its holdings in shares of ResMed by 25.0% during the fourth quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider’s stock valued at $696,523,000 after acquiring an additional 578,559 shares in the last quarter. Finally, Swedbank AB increased its stake in ResMed by 103.1% during the 4th quarter. Swedbank AB now owns 1,102,476 shares of the medical equipment provider’s stock valued at $265,553,000 after purchasing an additional 559,765 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Trading Up 1.0%

RMD opened at $200.49 on Friday. The business has a 50 day simple moving average of $203.31 and a two-hundred day simple moving average of $231.18. ResMed Inc. has a one year low of $180.26 and a one year high of $293.81. The firm has a market capitalization of $29.08 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 1.28 and a beta of 0.80. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33.

ResMed (NYSE:RMD – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. The firm had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.37 EPS. Analysts predict that ResMed Inc. will post 11.13 EPS for the current year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Thursday, May 14th. ResMed’s payout ratio is presently 23.14%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings cut ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Royal Bank Of Canada boosted their price objective on ResMed from $314.00 to $321.00 and gave the company an “outperform” rating in a research note on Friday, May 1st. Robert W. Baird set a $225.00 target price on ResMed in a research report on Friday, May 1st. JPMorgan Chase & Co. started coverage on shares of ResMed in a report on Wednesday, April 15th. They issued an “overweight” rating on the stock. Finally, Morgan Stanley reissued an “equal weight” rating and set a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $270.82.

Get Our Latest Research Report on ResMed

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction on Monday, June 8th. The stock was sold at an average price of $193.96, for a total transaction of $968,054.36. Following the transaction, the chief executive officer owned 466,256 shares in the company, valued at $90,435,013.76. This represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 16,973 shares of company stock worth $3,580,754 over the last three months. Insiders own 0.65% of the company’s stock.

ResMed Company Profile

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.